Innate Pharma S.A.
IPHA
$1.93
-$0.04-2.03%
NASDAQ
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 26.89M | 41.66M | 56.11M | 51.44M | 46.62M |
| Total Other Revenue | 9.67M | 10.13M | 10.53M | 9.83M | 9.08M |
| Total Revenue | 36.56M | 51.79M | 66.64M | 61.28M | 55.69M |
| Cost of Revenue | 58.03M | 59.50M | 60.58M | 61.00M | 61.08M |
| Gross Profit | -21.47M | -7.71M | 6.06M | 277.30K | -5.39M |
| SG&A Expenses | 20.26M | 20.08M | 19.78M | 20.12M | 20.33M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 78.28M | 79.57M | 80.36M | 81.11M | 81.41M |
| Operating Income | -41.73M | -27.78M | -13.71M | -19.84M | -25.72M |
| Income Before Tax | -36.82M | -22.56M | -8.20M | -36.07M | -63.44M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -36.82 | -22.56 | -8.20 | -36.07 | -63.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -29.60K | -58.80K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -36.82M | -22.56M | -8.20M | -36.10M | -63.50M |
| EBIT | -41.73M | -27.78M | -13.71M | -19.84M | -25.72M |
| EBITDA | -38.89M | -23.60M | -8.21M | -13.86M | -19.29M |
| EPS Basic | -0.46 | -0.28 | -0.10 | -0.45 | -0.80 |
| Normalized Basic EPS | -0.28 | -0.17 | -0.06 | -0.13 | -0.19 |
| EPS Diluted | -0.46 | -0.28 | -0.10 | -0.46 | -0.80 |
| Normalized Diluted EPS | -0.28 | -0.18 | -0.06 | -0.13 | -0.19 |
| Average Basic Shares Outstanding | 322.92M | 322.37M | 321.81M | 320.75M | 319.69M |
| Average Diluted Shares Outstanding | 322.92M | 327.95M | 330.85M | 329.79M | 328.73M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |